The pathogenesis of inflammatory bowel disease (IBD) is complex and largely unknown.
Until recently, research has focused on the study of protein regulators in inflammation to …

This study employs spectroscopy-based metabolic profiling of fecal extracts from healthy
subjects and patients with active or inactive ulcerative colitis (UC) and Crohn's disease (CD) …

Interleukin-33 (IL-33) is a novel member of the IL-1 cytokine family. It has been shown to
elicit a Th2-like cytokine response in immunocompetent cells through binding and activation …

AIM: To use microarray-based miRNA profiling of colonic mucosal biopsies from patients
with ulcerative colitis (UC), Crohn's disease (CD), and controls in order to identify new …

Use of the immunomodulators thiopurines and methotrexate (MTX) in the treatment of
inflammatory bowel disease (IBD), ie, Crohn's disease and ulcerative colitis (UC), is …

Inflammatory bowel disease (IBD) is a chronic intestinal disorder, with two main types:
Crohn's disease (CD) and ulcerative colitis (UC), whose molecular pathology is not well …

Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are
not always effectively treated using glucocorticoids and it may negatively affect the antitumor …

Background Retrospective studies suggest that for patients with ulcerative colitis (UC)
combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in …

Background Genome-wide gene expression (GWGE) profiles of mucosal colonic biopsies
have suggested the existence of a continuous inflammatory state in quiescent ulcerative …

Background One-third of inflammatory bowel disease (IBD) patients show no response to
infliximab (IFX) induction therapy, and approximately half of patients responding become …